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ABSTRACT
Osler-Weber-Rendu disease, also known as hereditary hemorrhagic telangiectasia (HHT) is a rare autosomal dominant genetic 
disorder that leads to abnormal blood vessel formation in the skin, mucous membrane and in organs such as lungs, liver, and brain. 
Here, we report the case of a 68-year-old postmenopausal woman who was admitted to our hospital following multiple episodes of 
hematemesis and melena during the past 5 days. Upper GI endoscopy revealed multiple telangiectasia with active spurting and gastric 
polyp. The patient was treated with 1 unit of packed red blood cells transfusion for anemia, Inj. Tranexamic acid 500 mg IV tid and Inj. 
Ondansetron 4 mg IV for hematemesis. Tab. Thalidomide 100 mg has been given for treating hereditary hemorrhagic telangiectasia. 
The treatment of HHT is only palliative, with no consensus on the best treatment option. It is essential to promote control of the 
disease as long as possible.
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Osler-Weber-Rendu disease, also known as hereditary hemorrhagic telangiectasia (HHT) is a rare autosomal dominant genetic disorder that leads to abnormal blood 
vessel formation in the skin, mucous membrane and in organs 
such as lungs, liver, and brain. In small blood vessels, these 
abnormalities are called telangiectasias and when they occur 
in larger vessels, they are called arteriovenous malformations 
(AVM). Both are a potential source of serious morbidity and 
mortality. 
Recent epidemiological studies revealed a prevalence of 
1:5000-8000 persons worldwide. HHT has a higher prevalence 
in the certain population such as in Afro-Carribean residents [1]. 
Incidence of HHT is difficult to determine because the severity 
of symptoms vary widely and HHT is widely distributed, 
affects about 1 in 5000 (0.02%). This condition is inherited 
in an autosomal dominant pattern. It can result in serious life-
threatening conditions, and still often undiagnosed by doctors 
since its manifestations are difficult to rule out the disease.
CASE REPORT
A 68-year-old postmenopausal woman was admitted to our 
hospital following multiple episodes of hematemesis and 
melena for the past 5 days. The patient has comorbidities such 
as mild pulmonary arterial hypertension and asthma and was 
under medications. She had multiple episodes of epistaxis, 
palpitations and abdominal pain. There was no history of 
bleeding gums and rectum, headache, seizure, visual disturbance 
Figure 1: Tiny polyps were evident at the fundus region and active 
spurting telangiectasia seen at the proximal body.
Figure 2: Multiple telangiectasia and small polyps were found at 
antrum and duodenum.
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or bluish discoloration of fingertips or nose. A family history of 
telangiectasia was present in her brother. On general examination, 
the patient was conscious, oriented, and anemic with pallor and 
had stable vitals. The abdominal tenderness was present and there 
was an absence of organomegaly.  
No abnormalities were detected on a chest X-ray. The laboratory 
workup at admission revealed the following: white blood cells - 
2,200cells/mm3; platelet count - 250,000/mm3; hemoglobin - 6.9 
g/dl and serum iron - 34 ug/dl. Investigations including bleeding 
time, coagulation time, prothrombin time (PT), activated partial 
thromboplastin time (aPTT), and stool occult blood reported to be 
normal. Endoscopy of the upper digestive tract was performed. 
Serum for antinuclear antibody (ANA), urine for hemoglobinuria 
and sickling test were found to be negative. 
Upper gastrointestinal endoscopy revealed multiple small, 
sessile, numerous telangiectasia in the pharynx and esophagus 
(Fig. 1). Tiny polyps were evident at the fundus region, active 
spurting telangiectasia was seen at the proximal body (Fig. 2), 
multiple telangiectasia and small polyps were found at the antrum 
and duodenum (Fig. 3) and active ooze was noted at the proximal 
body along the lesser curve.
The patient was treated with 1 unit of packed red blood 
cells (PRBC) transfusion for anemia, Inj. Tranexamic acid 500 
mg IV tid and Inj. Ondansetron 4 mg IV for hematemesis. Tab. 
Thalidomide 100 mg HS has been given for treating HHT. Hence, 
the severity of nasal bleed and hematemesis were significantly 
reduced, hemoglobin level improved and there were no side 
effects reported by the patient at subsequent follow-up.
DISCUSSION
The diagnosis of Osler-Weber-Rendu disease is based on the 
Curaçao criteria which consist of (a) epistaxis: spontaneous, 
recurrent nosebleeds, (b) telangiectasias: multiple, at 
characteristic sites (lips, oral cavity, fingers, nose), (c) visceral 
lesions such as gastrointestinal telangiectasias (with or without 
bleeding), pulmonary AVM, hepatic AVM, cerebral AVM, spinal 
AVM and (d) family history: a first-degree relative with HHT. 
The presence of 3 criteria indicate a definite diagnosis of the 
disorder; 2 criteria depicts a possible or suspected case and less 
than 2 means that unlikely the disease is present [1]. Also, the 
detection of the causative mutation through a molecular study is 
acceptable. Three genes are implicated in this disease. The first, 
ENG, is located on chromosome 9 (9q33-q34) and it encodes for 
endoglin. A mutation in this gene causes type 1HHT.A mutation 
in the ACVRL1 gene causes type 2HHT. This gene is located in 
the 12q11-q14 region of chromosome 12 and encodes for ALK1 
(activin receptor-like kinase) [1]. A small percentage of patients 
have juvenile polyposis/ hereditary HHT syndrome (JPHT) due 
to mutations in the MADH4 gene located on chromosome 18.
The primary and most common manifestation of HHT is 
usually epistaxis that begins during childhood or adolescence at a 
mean age of 12 years [2]. They typically occur on the face, lips, 
tongue, palms, and fingers including the periungual area and the 
nail bed. Telangiectasia are the dilated blood vessels that appear 
as thin spider web-like red and dark purple lesions that blanch 
with pressure. AVMs are abnormal connections between arteries 
and veins that bypass the capillary system. Patients with HHT 
have multiple AVMs throughout the body. However, the most 
important AVMs for which clinicians should screen are in the 
brain, lungs, GI tract, and liver. AVMs in the lung and brain can 
be asymptomatic [3].
The overall treatment of HHT is oriented towards the 
predominant clinical manifestation and its severity. The first step 
in epistaxis management should always be necessary for patient 
counseling and use of preventive measures within the home to 
prevent the nasal mucosa from becoming dry. These include 
nasal humidification, use of over-the-counter saline sprays or 
ointments to keep the nasal mucosa moist and avoidance of nasal 
trauma [4]. In a double-blind randomized controlled trial, 50 μg 
ethinyloestradiol and 1 mg norethisterone resulted in a significant 
reduction in transfusion requirements in 10 patients with a mean 
transfusion requirement of 19.4 packed cells units per year. These 
data have been extrapolated in clinical practice to patients with 
lesser degrees of hemorrhage not necessarily associated with 
regular transfusion requirements. 
The use of higher dose conjugated estrogens in the “hormone 
replacement” range of over 625 μg ethinyloestradiol equivalent or 
prothrombotic agents such as tranexamic acid and aminocaproic 
acid are also widespread in management of HHT related bleeding 
[5]. Hormonal or antifibrinolytic therapy may be used as an 
adjunct therapy to prevent ongoing bleeding. In patients that 
have liver AVMs, embolization is not recommended given the 
risk post-embolization necrosis and death. Surgical intervention 
should only be considered if they become symptomatic or develop 
complications. 
For those with significant hepatic AVM involvement, partial 
liver resection is a safe treatment option. If a patient’s hemoglobin 
and hematocrit are low, an upper endoscopy should be completed 
if the anemia is disproportionate to epistaxis. Iron supplementation 
should be initiated, either oral or intravenous (IV) and endoscopic 
cauterization can be considered. It is recommended that acute 
epistaxis be managed with low-pressure, less-traumatic packing 
techniques. In some studies, a mild benefit was shown for the use 
of humidifiers to prevent chronic epistaxis [5].
Anti-angiogenic factors can be useful in treating vascular 
malformations such as thalidomide that inhibits tumor necrosis 
Figure 3: Active ooze noted at the proximal body along the lesser 
curve.
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factor-alpha, thereby acting as a potent anti-angiogenic drug in 
case of this patient as well. Newer treatment modalities available 
are (a) hormone-related drugs containing estrogen. Anti-estrogen 
medications such as tamoxifen, raloxifene have been used to 
control HHT; (b) drugs that block blood vessel growth such as 
bevacizumab IV, pomalidomide, pazopanib; (c) drugs that slow 
disintegration of clots includes tranexamic acid [6].
Procedures to reduce frequency and severity of nosebleeds 
include are ablation that uses energy from lasers or a high-
frequency electrical current to seal the abnormal vessels that are 
causing nose bleed; skin graft which is done from another part of 
your body, usually thigh and surgical closing of nostrils in which 
connecting flaps of skin are used within the nose to permanently 
close the nostrils but this procedure is only done when other 
approaches failed [7,8].
CONCLUSION
Hereditary Hemorrhagic Telangiectasia is a fibrovascular 
dysplasia for which complete cure cannot be established. 
Repeated endoscopic hemostasis for all dilated capillary vessels 
could be effective in preventing relapse of hemorrhage. In short, 
management includes blood transfusion, antifibrinolytics, and 
surgical hemostasis.
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